Cargando…
Development of a Gene Risk Signature for Patients of Pancreatic Cancer
BACKGROUND: Pancreatic cancer is a highly malignant solid tumor with a high lethality rate, but there is a lack of clinical biomarkers that can assess patient prognosis to optimize treatment. METHODS: Gene-expression datasets of pancreatic cancer tissues and normal pancreatic tissues were obtained f...
Autores principales: | Liu, Tao, Chen, Long, Gao, Guili, Liang, Xing, Peng, Junfeng, Zheng, Minghui, Li, Judong, Ye, Yongqiang, Shao, Chenghao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759853/ https://www.ncbi.nlm.nih.gov/pubmed/35035831 http://dx.doi.org/10.1155/2022/4136825 |
Ejemplares similares
-
PLAGL1 is associated with prognosis and cell proliferation in pancreatic adenocarcinoma
por: Liang, Xing, et al.
Publicado: (2023) -
Development and validation of a four‐lipid metabolism gene signature for diagnosis of pancreatic cancer
por: Ye, Yanrong, et al.
Publicado: (2021) -
Signature for Prostate Cancer Based on Autophagy-Related Genes and a Nomogram for Quantitative Risk Stratification
por: Wen, Chenghao, et al.
Publicado: (2022) -
SYT8 promotes pancreatic cancer progression via the TNNI2/ERRα/SIRT1 signaling pathway
por: Fu, Zhiping, et al.
Publicado: (2021) -
Development of CT-Based Imaging Signature for Preoperative Prediction of Invasive Behavior in Pancreatic Solid Pseudopapillary Neoplasm
por: Huang, Wen-peng, et al.
Publicado: (2021)